Glenmark’s new ‘digital dose inhaler’ for asthma, COPD displays dose remaining in it – TheHealthSite


Moneycontrol.com

Glenmark's new 'digital dose inhaler' for asthma, COPD displays dose remaining in it
TheHealthSite
Pharmaceutical major Glenmark on Wednesday launched an inhaler for asthma and Chronic Obstructive Pulmonary Disease (COPD) patients that displays the medicine dose remaining in it. 'Digital dose inhaler or 'Digihaler' will enable the patients to track ...
Glenmark launches 'Digihaler' for asthma and COPD medicationpharmabiz.com
Glenmark Pharma launches digital inhaler for asthma patientsETCIO.com
Glenmark launches digital dose inhaler for asthma patientsMoneycontrol.com

all 6 news articles »

Glenmark launches digital inhaler for asthma, obstructive pulmonary disease – Livemint


Livemint

Glenmark launches digital inhaler for asthma, obstructive pulmonary disease
Livemint
Photo: Mint. Hyderabad: Glenmark Pharmaceuticals Ltd on Wednesday launched Digihaler, India's first digital dose inhaler for asthma and chronic obstructive pulmonary disease (COPD) patients. The product costs Rs.300-450, depending on the strength and ...
Glenmark launches electronic inhaler for asthma patientsHindu Business Line

all 6 news articles »

Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta – Yahoo News


Newsmax

Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta
Yahoo News
The multi-center, open-label, randomized, controlled study was conducted to compare the effectiveness and safety profile of Relvar Ellipta with existing COPD usual care, including long-acting muscarinic antagonists, long-acting beta2-agonists, and ...
COPD Drug Successful in Large TrialNewsmax
GlaxoSmithKline plc (ADR) Moves Ahead in COPD TreatmentBusiness Finance News
GSK's Relvar Ellipta hits the mark in COPD trialPharmaTimes
Drug Discovery & Development -FiercePharma
all 34 news articles »

Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta – Zacks.com


Newsmax

Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta
Zacks.com
The multi-center, open-label, randomized, controlled study was conducted to compare the effectiveness and safety profile of Relvar Ellipta with existing COPD usual care, including long-acting muscarinic antagonists, long-acting beta2-agonists, and ...
COPD Drug Successful in Large TrialNewsmax
GSK Announces Impressive New Data for COPD DrugDrug Discovery & Development
GSK's Relvar Ellipta hits the mark in COPD trialPharmaTimes
FiercePharma -Seeking Alpha -Sonoran Weekly Review
all 23 news articles »